Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Holders of 5% or more of NKTR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nektar Therapeutics, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G | 7.40%1.28M shares | New | Jul 9, 20251 filing | Jul 9, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.70%12.5M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Susquehanna Securities, LLC | 13G | 6.30%1.24M shares | New | Nov 13, 20251 filing | Nov 13, 2025 | SEC |
| Integrated Core Strategies (US) LLC | 13G | 5.40%932.9K shares | New | Jul 3, 20251 filing | Jul 3, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Nektar Therapeutics, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20254:31 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 2.20%418.5K shares | −3.52 ppfrom 5.72%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:23 PM ET | TCG Crossover GP II, LLCand 2 others | 13G/A | 0.00%0 shares | −9.30 ppfrom 9.30%Below 5% | Sep 30, 2025 | SEC |
| Nov 13, 20255:45 PM ET | Susquehanna Securities, LLCand 1 other | 13G | 6.30%1.24M shares | New | Sep 30, 2025 | SEC |
| Aug 14, 20254:45 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 5.72%709.8K shares | New | Jun 30, 2025 | SEC |
| Aug 14, 20254:14 PM ET | TCG Crossover GP II, LLCand 2 others | 13G/A | 9.30%1.93M shares | – | Jun 30, 2025 | SEC |
| Jul 18, 202512:10 PM ET | BlackRock, Inc. | 13G/A | 1.60%203.0K shares | –Below 5% | Jun 30, 2025 | SEC |
| Jul 9, 20254:39 PM ET | Biotechnology Value Fund L Pand 9 others | 13G | 7.40%1.28M shares | New | Jul 1, 2025 | SEC |
| Jul 3, 20252:07 PM ET | Integrated Core Strategies (US) LLCand 3 others | 13G | 5.40%932.9K shares | New | Jun 27, 2025 | SEC |
| May 15, 20253:35 PM ET | Samlyn Capital, LLCand 2 others | 13G/A | 0.00%0 shares | −5.20 ppfrom 5.20%Below 5% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 6.70%12.5M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20251:49 PM ET | Samlyn Capital, LLCand 2 others | 13G | 5.20%9.67M shares | New | Dec 31, 2024 | SEC |
| Feb 14, 202512:08 PM ET | Eventide Asset Management, LLCand 2 others | 13G/A | 3.61%6.65M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20258:43 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 1.07%1.98M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Nektar Therapeutics shares.
No Form 144 notices for Nektar Therapeutics are on file.